2024
Activated sputum eosinophils associated with exacerbations in children on mepolizumab
Wilson G, Knight J, Liu Q, Shelar A, Stewart E, Wang X, Yan X, Sanders J, Visness C, Gill M, Gruchalla R, Liu A, Kattan M, Khurana Hershey G, Togias A, Becker P, Altman M, Busse W, Jackson D, Montgomery R, Chupp G. Activated sputum eosinophils associated with exacerbations in children on mepolizumab. Journal Of Allergy And Clinical Immunology 2024, 154: 297-307.e13. PMID: 38485057, PMCID: PMC11305967, DOI: 10.1016/j.jaci.2024.01.031.Peer-Reviewed Original ResearchAirway eosinophilsSputum eosinophilsPatients treated with mepolizumabPlacebo-controlled clinical trialAnti-IL-5 treatmentEffect of mepolizumabEosinophil subpopulationsSevere eosinophilic asthmaAnti-interleukin-5Expression of CD62LFrequency of exacerbationsEosinophilic asthmaActivation markersSputum samplesUnsupervised cluster analysisMepolizumabTreatment armsReduce exacerbationsCD62LClinical trialsExacerbationMass cytometryEosinophilsExacerbation riskIntracellular markers
2023
Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goalsReal-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study
Chupp G, Heaney L, Price R, Brusselle G, Gardiner F, Raimondi A, Chaudhuri R, Howarth P. Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study. Journal Of Allergy And Clinical Immunology 2023, 151: ab20. DOI: 10.1016/j.jaci.2022.12.066.Peer-Reviewed Original Research
2017
Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Tria
Trevor J, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L, Chupp G, Magnan A, Brinke A. Mepolizumab Improves Lung Function and Exacerbation Rates in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Tria. Journal Of Allergy And Clinical Immunology 2017, 139: ab380. DOI: 10.1016/j.jaci.2016.12.912.Peer-Reviewed Original ResearchSevere eosinophilic asthmaEosinophilic asthmaExacerbation rateLung functionPhase IIIbMepolizumabPlaceboAsthmaIIIBMepolizumab Significantly Improves Health Status and Asthma Control in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Trial
Chupp G, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L, Trevor J, Magnan A, Brinke A. Mepolizumab Significantly Improves Health Status and Asthma Control in Severe Eosinophilic Asthma: The Musca Study - a Phase IIIb Randomized, Placebo-Controlled Trial. Journal Of Allergy And Clinical Immunology 2017, 139: ab380. DOI: 10.1016/j.jaci.2016.12.911.Peer-Reviewed Original ResearchSevere eosinophilic asthmaEosinophilic asthmaAsthma controlPhase IIIbHealth statusMepolizumabPlaceboAsthmaIIIBTrials